Bolivia (Plurinational State of)
Tuberculosis profile
Population  2013 11 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.43 (0.18–0.78) 4 (1.7–7.3)
Mortality (HIV+TB only) 0.12 (0.092–0.16) 1.2 (0.86–1.5)
Prevalence  (includes HIV+TB) 21 (11–34) 196 (102–319)
Incidence  (includes HIV+TB) 13 (12–15) 123 (110–140)
Incidence (HIV+TB only) 0.39 (0.35–0.51) 3.6 (3.3–4.8)
Case detection, all forms (%) 63 (56–71)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.2 (0.4–2.6) 11 (8.9–14)
MDR-TB cases among notified pulmonary
TB cases
72 (24–160) 85 (67–110)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 5 419   555
Pulmonary, clinically diagnosed 575   59
Extrapulmonary 1 668   51
       
Total new and relapse 8 327    
Previously treated, excluding relapses 146    
Total cases notified 8 473    
Among 8 327 new and relapse cases:
435 (5%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 329 (6%) 395 (49%) 1 277
Laboratory-confirmed RR-/MDR-TB cases     96
Patients started on MDR-TB treatment     47
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 908 (70)
HIV-positive TB patients 170 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 31 (18)
HIV-positive TB patients on antiretroviral therapy (ART) 140 (82)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 84
Previously treated cases registered in 2012 76
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 63
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 5.4
Culture (per 5 million population) 35.1
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 3.1
% Funded domestically 32%
% Funded internationally 28%
% Unfunded 39%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-03 Data: www.who.int/tb/data